PrEP: latest news

PrEP resources

PrEP features

PrEP news from aidsmap

More news

PrEP news selected from other sources

  • HIV research and advocacy groups release recommendations on uptake and expansion of HIV pre-exposure prophylaxis in California

    Though the use of PrEP has recently begun to rise among those at risk of HIV infection, it is still being used by very few who need it most, and access to culturally competent PrEP services still lags behind.

    02 September 2015 | Project Inform press release
  • Large Study of PrEP Use in Clinical Practice Shows No New HIV Infections

    In one of the first and largest published evaluations of the use of preexposure prophylaxis (known as PrEP) to prevent HIV infection in a clinical practice setting, researchers at Kaiser Permanente found no new HIV infections among patients during more than 2.5 years of observation. The study was published today in the journal Clinical Infectious Diseases.

    02 September 2015 | Kaiser Permanente press release
  • It’s time to drop gay Atlanta’s barriers to PrEP

    PrEP, prophylactic treatment that prevents HIV infection, should be made accessible to every single person in the U.S. who is at risk for HIV infection. This should be the primary goal of gay activism in the next decade. There are certainly many other valid goals for ASOs, and they should be lauded for their successes. There is more to AIDS activism than simply viral load and PrEP adherence. But if the CDC prediction of half of us getting infected is accurate, nothing will seem more important 28 years from now than preventing these cases from happening in the first place. Our community’s disgrace this century will be its failure to embrace the greatest bridge to an HIV vaccine we’ve ever encountered.

    01 September 2015 | Project Q Atlanta
  • Gilead applies for PrEP approval in Canada

    Gilead has applied to Health Canada for Truvada to be approved as PrEP – HIV pre-exposure prophylaxis. Truvada is not approved as PrEP yet in Canada which means doctors must prescribe it off-label and it is not yet on any provincial drug plan formularies outside of Quebec. Gilead Pharmaceuticals has now formally submitted its application to Health Canada for Truvada to also be approved for a preventative indication. Much of this can be attributed to a petition launched in April by several HIV and gay men’s health organizations in Canada, calling on Gilead to apply to Health Canada.

    27 August 2015 | Homoculture.ca
  • Where Do I Fit In? PrEP and Transgender Men

    There aren’t guidelines about Truvada-based PrEP use for transgender men who have sex with men because there haven’t been any studies specifically looking at how the drug works in our bodies. In fact, major PrEP clinical efficacy trials have not included transgender men in any of their study populations to date.

    26 August 2015 | BETA blog
  • High rate of mental health issues found among some PEP users

    Researchers in Boston found that people who sought PEP had a high rate of mental health issues. The Boston team strongly encourages healthcare providers who prescribe PEP to screen and treat potential patients for mental health issues.

    26 August 2015 | CATIE
  • PrEPosterous gender health inequality?

    PrEP (Pre Exposure Prophylaxis) is a highly effective “game changer". Women should get excited right? Well, perhaps not – it’s not yet clear if we’ll get our hands on it.

    20 August 2015 | NAT
  • AIDS Healthcare Foundation Cedes Ground in Anti-PrEP Fight

    AIDS Healthcare Foundation, which has long waged a vociferous and largely isolated battle against Truvada as PrEP, has finally begun to capitulate, offering measured support for the HIV prevention method.

    19 August 2015 | AIDSMeds
  • PrEP Seen as a Big Part of White House's New HIV Strategy

    HIV awareness groups say providing better access to the drug is essential to lower the rate of infection.

    10 August 2015 | Healthline
  • HIV Prevention Pill Remains A Tough Sell Among Gay Latinos

    In California, New York, Texas and elsewhere, health workers are trying to get more high-risk Latino men to use the drug, Truvada. AltaMed's efforts are being paid for by Gilead, the pharmaceutical company that makes Truvada.

    07 August 2015 | NPR
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.